Respiratory medicine

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS101
Academic Journal
Presents an abstract of the research manuscript `Adenovirus E1A protein is present in lungs of patients with cystic fibrosis,' by W.M. Elliott et al.


Related Articles

  • Vehicles for gene therapy. Wilson, James M. // Nature;10/21/1993, Vol. 365 Issue 6448, p691 

    Discusses a report on a trial of cystic fibrosis gene therapy in humans. Use of recombinant adenovirus; Identification of the gene responsible for cystic fibrosis.

  • Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Jooss, K; Turka, L A; Wilson, J M // Gene Therapy;Mar1998, Vol. 5 Issue 3, p309 

    Adenoviral vectors deleted of E1 are attractive vehicles for in vivo gene therapy because efficient gene transfer can be achieved. Immune responses to the vector and vector-transduced cells lead to destruction of target cells, inflammation and difficulties with vector readministration. Immune...

  • Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro. Arcasoy, S M; Latoche, J D; Gondor, M; Pitt, B R; Pilewski, J M // Gene Therapy;Jan1997, Vol. 4 Issue 1, p32 

    Recombinant adenoviruses are being developed for gene therapy for cystic fibrosis and other lung diseases, and for prevention and treatment of vascular thrombosis. A major limitation to the clinical utility of adenoviruses is the low efficiency of gene transfer achieved in vivo. In addition,...

  • Efficient CFTR expression from AAV vectors packaged with promoters — the second generation. Wang, D; Fischer, H; Zhang, L; Fan, P; Ding, R X; Dong, J // Gene Therapy;Apr99, Vol. 6 Issue 4, p667 

    Gene therapy studies of cystic fibrosis (CF) have shown that AAV-based vector was efficient in transferring but not in expressing the CFTR cDNA in the target cells. The levels of CFTR gene expression were limited by the small packaging capacity of AAV because it had been difficult to package the...

  • Activation of NF-kB mediates ICAM-1 induction in respiratory cells exposed to an adenovirus-derived vector. Melotti, P; Nicolis, E; Tamanini, A; Rolfini, R; Pavirani, A; Cabrini, G // Gene Therapy;Sep2001, Vol. 8 Issue 18, p1436 

    Gene transfer to the respiratory tract by replication-deficient adenoviruses is limited by the induction of inflammatory and immune responses. We previously demonstrated that a E1E3-deleted recombinant adenovirus carrying the expression cassette for the cystic fibrosis gene (Ad.CFTR) upregulates...

  • The development of gene therapy for diseases of the lung. Gill, D. R.; Davies, L. A.; Pringle, I. A.; Hyde, S. C. // Cellular & Molecular Life Sciences;Feb2004, Vol. 61 Issue 3, p355 

    The development of a successful gene therapy has many stages, including preclinical testing in animal models and proof of principle clinical studies. A variety of diseases affect the lung, which are candidates for gene therapy; this review will mainly focus on the diseases that have attracted...

  • Mechanism by which calcium phosphate coprecipitation enhances adenovirus-mediated gene transfer. Walters, R W; Welsh, M J // Gene Therapy;Nov99, Vol. 6 Issue 11, p1845 

    Delivery of a normal copy of CFTR cDNA to airway epithelia may provide a novel treatment for cystic fibrosis lung disease. Unfortunately, current vectors are inefficient because of limited binding to the apical surface of airway epithelia. We recently reported that incorporation of adenovirus in...

  • tgAAVCF: will Phase II failure be the straw that breaks investors' backs?  // PharmaWatch: Monthly Review;May2005, Vol. 4 Issue 5, p21 

    The article reports on the failure of the phase II clinical trial of the Targeted Genetics' proprietary adeno-associated virus vector cystic fibrosis (tgAAVCF) therapy in the U.S. The phase II clinical trials reveals that it had failed to improve lung function in patients with mild to moderate...

  • 474. Deletion of All Membranous Genes of Recombinant Sendai Virus Results in the Dramatic Reduction of Toxicity for Pulmonary Gene Transfer in Neonatal Mice. Tanaka, Sakura; Yonemitsu, Yoshikazu; Hasegawa, Mamoru; Taguchi, Tomoaki; Sueishi, Katsuo // Molecular Therapy;Jun2006, Vol. 13, pS184 

    Background and Aim:We previously demonstrated the dramatically high efficiency of recombinant Sendai virus (SeV) for pulmonary gene transfer, 1,000-100,000 fold over that via adenoviruses, and suggested that its possible application for gene therapy of cystic fibrosis (CF) (Yonemitsu Y et al....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics